TUSSICAPS 5mg/4mg CII
Generic Name and Formulations:
Hydrocodone bitartrate 5mg, chlorpheniramine maleate 4mg; as polistirex; ext-rel caps; contains alcohol.
Indications for TUSSICAPS 5mg/4mg:
Cough and upper respiratory symptoms.
1 cap (10mg/8mg) every 12hrs; max 2caps/24hrs.
<6yrs: see Contraindications. 6–11yrs: 1 cap (5mg/4mg) every 12hrs; max 2caps/24hrs.
Children <6yrs of age (risk of fatal respiratory depression).
Respiratory depression. Post–op. Pulmonary disease. Head injury. Increased intracranial pressure. Glaucoma. Asthma. GI or GU obstruction. Acute abdomen. Severe hepatic or renal impairment. Hypothyroidism. Addison's disease. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Antitussive + antihistamine.
Additive CNS depression with alcohol, other CNS depressants, tricyclic antidepressants, MAOIs. Paralytic ileus with concurrent anticholinergics.
Nausea, vomiting, CNS and respiratory depression, ureteral and vesical sphincter spasm, chest tightness, abuse potential, anticholinergic effects, rash, pruritis.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|